Literature DB >> 7334811

Development of a RIA for clonidine and its comparison with the reference methods.

D Arndts, H Stähle, H J Förster.   

Abstract

A radioimmunoassay for clonidine was optimized by introducing, as a tracer ligand, an iodinized clonidine derivative specifically labeled with more than 500 Ci/mMol. The detection limit of clonidine was 10 pg/ml. The high assay specificity was demonstrated by a double isotope technique. The intraassay coefficient of variance (VK) was less than 4% for any concentration, the interassay VK did not exceed 8.3%. The assay reliability was increased when the plasma samples were diluted 1:5, prior to analysis, in normal human blood plasma, which was also used for the preparation of the calibration samples. In a comparative manner, this assay system was subjected to double-blind accuracy control tests, including all other reference methods so far described for clonidine analysis in blood plasma samples. The RIA technique presented here turned out to be the most sensitive and most reliable method, requiring, moreover, the smallest volumes of blood plasma (0.05 ml). This procedure was appropriate for routine tests, since one technician could perform 500 sample analyses a day. The advantages and disadvantages of each method are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7334811     DOI: 10.1016/0160-5402(81)90069-3

Source DB:  PubMed          Journal:  J Pharmacol Methods        ISSN: 0160-5402


  9 in total

1.  New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man.

Authors:  D Arndts; J Doevendans; R Kirsten; B Heintz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  New aspects in the metabolism of alinidine in man.

Authors:  D Arndts; H J Forster
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

3.  Alpha-2 adrenergic activity in perimenopausal women.

Authors:  G Del Rio; R Menozzi; L Della Casa; M G Venneri; G Zizzo; P Marrama; A Velardo
Journal:  J Endocrinol Invest       Date:  1997-11       Impact factor: 4.256

4.  Pharmacokinetics and pharmacodynamics of transdermally administered clonidine.

Authors:  D Arndts; K Arndts
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  An assessment of the contribution of clonidine metabolised from alinidine to the cardiovascular effects of alinidine.

Authors:  D W Harron; D Arndts; M Finch; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

6.  A circulating substance cross-reacting with antiimidazoline antibodies. Detection in serum in relation to essential hypertension.

Authors:  M Dontenwill; A Molines; A Verdun; G Bricca; S Laurent; P Bousquet
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

7.  Transdermal clonidine application: long-term results in essential hypertension.

Authors:  H Groth; H Vetter; J Knüsel; E Foerster; W Siegenthaler; W Vetter
Journal:  Klin Wochenschr       Date:  1984-10-01

Review 8.  Transdermal clonidine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  M S Langley; R C Heel
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

Review 9.  Clinical pharmacokinetics of clonidine.

Authors:  D T Lowenthal; K M Matzek; T R MacGregor
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.